NetApp Teams with VMware, AWS to Help Customers Modernize and Scale Enterprise Workloads on the Cloud
15.9.2022 04:31:00 EEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, in collaboration with VMware, Inc. and Amazon Web Services (AWS), today announced the general availability of Amazon FSx for NetApp ONTAP with VMware Cloud on AWS, the first and only native AWS cloud storage service certified and supported as a supplemental datastore for VMware Cloud on AWS.
With this new datastore solution, enterprises can quickly, easily and cost-effectively move their enterprise, data-demanding workloads to VMware Cloud on AWS. This allows organizations to scale cloud storage independent of cloud compute to optimize costs, deploy new modern applications with the speed and scalability of the cloud, and maximize the value of their existing IT investments. Additionally, organizations can gain access to the rich data management, protection, and efficiency benefits of ONTAP utilized by nearly twenty thousand VMware customers running on-premises today.
“Our strong relationship, deep integration and joint innovation with both VMware and AWS hits another milestone, which helps make it easier for organizations to efficiently move enterprise workloads to the cloud,” said Phil Brotherton, Vice President, Solutions & Alliances at NetApp. “VMware customers running on NetApp or non-NetApp storage onpremises can now access the enterprise-class public cloud storage services and features of ONTAP, all running on AWS, as the first certified and supported supplemental datastore to VMware Cloud on AWS.”
“The majority of enterprises today run workloads on a VMware platform. Whether that is on premises or in VMware Cloud on AWS, they want to be able to leverage consistency in operations and architecture,” said Narayan Bharadwaj, Vice President, Cloud Solutions at VMware. “AWS, NetApp and VMware are giving customers the flexibility to buy and configure cloud storage independent of compute to meet the needs of a wide variety of enterprise applications. Our co-innovation will enable customers moving enterprise workloads to the cloud to cost-optimize and better scale their environments.”
New benefits from this certified and supported offering include improved:
- Speed: Migrate data-demanding on-premises vSphere-based workloads with NetApp or non-NetApp storage to VMware Cloud on AWS with reduced complexity – leveraging consistent VMware-to-VMware migration for workloads combined with the speed, performance and simplicity of ONTAP via Amazon FSx for NetApp ONTAP.
- Cost Control: Scale VMware Cloud compute independent of cloud storage to optimize cost at scale for demanding workloads combined with the rich data efficiency features of ONTAP to control cost at scale, including dedupe, compression, compaction, and thin provisioning.
- Efficiency: Leverage existing VMware-centric resource investments including people, processes and technologies from on-premises and on the cloud for consistency of operations.
In addition, partners of NetApp, VMware and AWS can benefit from this innovation to expand their current offerings around VMware Cloud in multiple ways:
- Unlock new business for hybrid and cloud-native workloads through breaking down cost barriers to migrating enterprise workloads through right-sizing cloud compute and cloud storage.
- Expand existing cloud services helping customers plan, design, deploy and optimize enterprise hybrid and cloud-native solutions for data-demanding workloads.
- Reduce risk for their clients through integrated and supported cloud solutions from NetApp and VMware to help customers migrate, extend or protect enterprise workloads to the cloud with confidence.
“As a leading multi-brand provider of full stack IT solutions, our customers rely on us to deliver solutions and services to help them manage their most data-demanding workloads,” said Troy Brick-Margelofsky, Digital Infrastructure Team Lead at CDW. “With Amazon FSx for NetApp ONTAP as a certified and supported datastore for VMware Cloud, we can now help customers move workloads on to the cloud quickly and efficiently, saving them time, money, and resources with the added benefit of integration with the complete NetApp portfolio.”
Amazon FSx for NetApp ONTAP provides fully managed shared storage on AWS with the popular data access and management capabilities of ONTAP. The solution allows organizations to easily migrate applications and run them on AWS, with ONTAP’s enterprise-grade storage workflows and data management capabilities, regardless of their on-premises storage provider.
Amazon FSx for NetApp ONTAP supplemental datastore for VMware Cloud on AWS is available today.
Additional Resources
- VMware Announcement
- Blog: Announcing VMware Cloud on AWS integration with Amazon FSx for NetApp ONTAP
- Blog: The Power of Partnerships: Taking Multi-Cloud Mainstream
- Amazon FSx for NetApp ONTAP
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services, and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
VMware and vSphere are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005373/en/
Contact information
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom